The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present its ONCO Prime ...

Under the leadership of Summit Therapeutics Co-CEO Maky Zanganeh, shares have risen 17-fold, bollstered by positive data on its leading drug candidate. In the ultra-competitive world of cancer ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net ...

Bob Duggan & Maky Zanganeh, Summit Therapeutics co-CEOs, join 'Fast Money' to talk its lung cancer drug and continuing ...

Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence. A biotech stock surging that much ...